Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Forma Therapeutics Holdings

Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout appeared first on Investor's Business Daily.

Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout

It's a newsworthy morning as Novo Nordisk (NYSE: NVO ) just announced that it will acquire Forma Therapeutics (NASDAQ: FMTX ). This is a $1.1 billion deal that will allow Novo Nordisk to expand its portfolio of blood disorder treatments.

Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News

Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.

Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion

Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.

Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal

Forma Therapeutics Holdings Inc. FMTX, +1.67% announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk NVO, +0.06% NOVO.B, -0.59% in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m.

Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion

Eli Lilly

Given that less than 3% of the 110 million obese Americans are being treated with drugs, new medications from Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) could fatten the bottom line of both companies along with their share prices.

Novo Nordisk, Eli Lilly Could Fatten Up on Weight-Loss Treatments

Albertsons Companies

Dollar General

The notion of a looming housing market crash appears to be picking up steam. There are multiple signs the ongoing correction could morph into something worse.

3 Stocks to Buy Before the Housing Market Crashes

A true compounder, Novo Nordisk is positioning itself beyond basal insulin amid market and government pressures. Crucial to this strategy is its fledgling Obesity Care unit, buoyed by successes like Wegovy.

Novo Nordisk: Assessing Hype Towards Obesity Care Following The Q2 Results Drop, Story Is Intact

Novo Nordisk (NVO) completes the phase II study evaluating CagriSema, a combination of semaglutide and cagrilintide for treating type II diabetes.

Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema

Bagsværd, Denmark , 2 2 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide.

Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes

NVO had excellent results in the past and a promising position to profit even further. Its pipeline should support good revenue and earnings growth in the coming years.

Novo Nordisk: Looming Danger In An Excellent Business

Bagsværd , Denmark, 15 August 202 2 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Novo Nordisk A/S: Share repurchase programme

ChargePoint Holdings

McCormick

QuantumScape

Shopify

Vista Oil & Gas SAB de CV

The current market conditions aren't conducive for short-term investing. It's notoriously difficult to pick winning stocks with a limited time horizon, and it becomes doubly true in this extremely volatile market!

7 Long-Term Stocks to Buy Before the Bull Market Returns

Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates

Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy on Thursday, saying there was nothing unusual about a slight delay in its availability.

Obesity drug supply delay not unusual says Novo Nordisk CEO

Novo Nordisk A/S (NVO) Q2 2022 Earnings Conference Call August 3, 2022 1:30 PM ET Company Participants Lars Fruergaard Joergensen - Chief Executive Officer Camilla Sylvest - Executive Vice President & Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President & Head of North America Operations Martin Holst Lange - Executive Vice President & Head of Development Karsten Munk Knudsen - Chief Financial Officer Conference Call Participants Peter Verdult - Citi Wimal Kapadia - Bernstein Matthew Weston - Credit Suisse Sachin Jain - Bank of America Simon Mather - BNP Paribas Exane Martin Parkhøi - SEB Michael Novod - Nordea Richard Vosser - JPMorgan Kerry Holford - Berenberg Mark Purcell - Morgan Stanley Operator Good evening. This is the conference operator.

Novo Nordisk A/S (NVO) CEO Lars Fruergaard Joergensen on Q2 2022 Results - Earnings Call Transcript

Danish drugmaker Novo Nordisk missed quarterly views Wednesday, but raised its full-year outlook. Still, NVO stock tumbled.

Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO Stock

Danish drugmaker Novo Nordisk on Wednesday lifted its sales and operating profit outlook for the year on the back of strong first-half earnings.

Novo Nordisk raises 2022 outlook after strong first half

3 August 2022 - Financial report for the period 1 January 2022 to 30 June 2022

Novo Nordisk's sales increased by 25% in Danish kroner and by 16% at constant exchange rates to DKK 83.3 billion in the first six months of 2022

Bagsværd, Denmark , 29 July 2022 – Novo Nordisk today announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes.

Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3

An obese population could drive competition toward a valuable market.

2 Pharma Giants With Momentum That Could Carry Through 2030

Shares of Marinus Pharmaceuticals Inc. MRNS, +4.13% gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 million to Novo Nordisk NVO, +1.19% . Marinus CFO Steven Pfanstiel told investors in a news release that the sale "extends our cash runway into the fourth quarter of 2023.

Marinus to sell rare-disease voucher to Novo Nordisk for $110 million

I wrote about Novo Nordisk a few months back, and called the company overvalued and a "Hold". It's time to update that thesis in today's market, and following a 5% drop. The company is still expensive, but we should be aware of the fact that Novo Nordisk does deserve a fair bit of premium here - because of the company's quality.

Updating On Novo Nordisk: Still Overvalued

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint

The Health Care sector is seen as a safety trade over recent weeks as global equities sputter. Novo Nordisk has a pipeline of drugs that should support high earnings growth in the coming years.

News for Novo Nordisk Stock (NVO)